1. Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population 
Jonathan E. Brammer, Alexander Stentz, James Gajewski, Peter Curtin, Brandon Hayes-Lattin, Tibor Kovacsovics, Jose F. Leis, Gabrielle Meyers, Eneida Nemecek, Nan Subbiah, Rachel Frires, Gundula Palmbach, Galit Perets Avraham, Susan Slater, Richard T. Maziarz 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 1, Pages (January 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Kaplan-Meier estimates of OS and PFS. With a median follow-up of 3.2 years in living patients, the 1-year OS was 60% and 2-year OS 48%. The estimated 3-year and 5-year OS were 42% and 29%, respectively. With a median follow-up of 3.2 years in living patients, the 1-year PFS was 48% and 2-year PFS 39%. Estimated 3- and 5-year PFS based on Kaplan-Meier analysis were estimated at 35% and 29%, respectively.
Biology of Blood and Marrow Transplantation  , 89-96DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Cumulative incidence of NRM. With a median follow-up of 3.2 years in living patients, the 1-year NRM was 27% and 2-year NRM 33%. Cumulative incidence of NRM at 3 and 5 years is estimated at 26% and 34%, respectively. (B) Cumulative incidence of relapse. The cumulative incidence of relapse was 29% at 1 year and 33% at 2 years. With a median follow-up of 3.2 years in living patients, the 1-year RM was 13% and 2-year RM was 20%.
Biology of Blood and Marrow Transplantation  , 89-96DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions